Your browser doesn't support javascript.
loading
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
Heerspink, Hiddo J L; Perco, Paul; Mulder, Skander; Leierer, Johannes; Hansen, Michael K; Heinzel, Andreas; Mayer, Gert.
Affiliation
  • Heerspink HJL; Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30 000, 9700 AD, Groningen, the Netherlands. h.j.lambers.heerspink@umcg.nl.
  • Perco P; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.
  • Mulder S; Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30 000, 9700 AD, Groningen, the Netherlands.
  • Leierer J; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.
  • Hansen MK; Cardiovascular and Metabolic Disease Research, Janssen Research & Development, LLC, Spring House, PA, USA.
  • Heinzel A; emergentec biodevelopment GmbH, Vienna, Austria.
  • Mayer G; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.
Diabetologia ; 62(7): 1154-1166, 2019 07.
Article in En | MEDLINE | ID: mdl-31001673
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrosis / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors / Inflammation / Kidney Diseases Type of study: Prognostic_studies Limits: Humans Language: En Journal: Diabetologia Year: 2019 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrosis / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors / Inflammation / Kidney Diseases Type of study: Prognostic_studies Limits: Humans Language: En Journal: Diabetologia Year: 2019 Type: Article Affiliation country: Netherlands